CA2725749A1 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same - Google Patents

Novel compounds, pharmaceutical compositions containing same, and methods of use for same Download PDF

Info

Publication number
CA2725749A1
CA2725749A1 CA2725749A CA2725749A CA2725749A1 CA 2725749 A1 CA2725749 A1 CA 2725749A1 CA 2725749 A CA2725749 A CA 2725749A CA 2725749 A CA2725749 A CA 2725749A CA 2725749 A1 CA2725749 A1 CA 2725749A1
Authority
CA
Canada
Prior art keywords
group
compound
comprised
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2725749A
Other languages
English (en)
French (fr)
Inventor
Craig A. Townsend
Rajaa El Meskini
Kandasamy Subburaj
Susan Medghaichi
Jill Marie Sturdivant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FASgen Inc
Original Assignee
Johns Hopkins University
FASgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, FASgen Inc filed Critical Johns Hopkins University
Publication of CA2725749A1 publication Critical patent/CA2725749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60Two oxygen atoms, e.g. succinic anhydride

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
CA2725749A 2008-06-02 2009-06-02 Novel compounds, pharmaceutical compositions containing same, and methods of use for same Abandoned CA2725749A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12904408P 2008-06-02 2008-06-02
US61/129,044 2008-06-02
US19312708P 2008-10-30 2008-10-30
US61/193,127 2008-10-30
PCT/US2009/045945 WO2009149066A1 (en) 2008-06-02 2009-06-02 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Publications (1)

Publication Number Publication Date
CA2725749A1 true CA2725749A1 (en) 2009-12-10

Family

ID=41398475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2725749A Abandoned CA2725749A1 (en) 2008-06-02 2009-06-02 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Country Status (6)

Country Link
US (1) US20110288052A1 (enExample)
EP (1) EP2285215A4 (enExample)
JP (1) JP2011521978A (enExample)
CN (1) CN102111998A (enExample)
CA (1) CA2725749A1 (enExample)
WO (1) WO2009149066A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
CA2849207A1 (en) * 2010-11-24 2012-05-31 Craig Townsend Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compounds
WO2014011973A2 (en) * 2012-07-13 2014-01-16 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
EP3220901B1 (en) 2014-11-20 2020-02-19 VIB vzw Means and methods for treatment of early-onset parkinson's disease
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CN114773241A (zh) * 2022-04-20 2022-07-22 益丰新材料股份有限公司 一种巯基羧酸酯的连续化合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062786A (en) * 1976-09-24 1977-12-13 Exxon Research And Engineering Company Lactone oxazolines as oleaginous additives
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
EP1539730A4 (en) * 2002-07-09 2007-03-28 Fasgen Inc NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHOD FOR THEIR APPLICATION
WO2008057585A1 (en) * 2006-11-08 2008-05-15 Fasgen Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Also Published As

Publication number Publication date
WO2009149066A1 (en) 2009-12-10
JP2011521978A (ja) 2011-07-28
US20110288052A1 (en) 2011-11-24
EP2285215A4 (en) 2012-04-04
CN102111998A (zh) 2011-06-29
EP2285215A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
AU2003265267B2 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US6187799B1 (en) Inhibition of raf kinase activity using aryl ureas
CA2725749A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
JP2011521978A5 (enExample)
AU2003248810B2 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CA2668840A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
AU2005249437A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CN114846000B (zh) 2-氨基-N-(氨基-氧代-芳基-λ6-亚硫烷基)乙酰胺化合物及其治疗用途
WO2007014249A2 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029761A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140602

FZDE Discontinued

Effective date: 20160602